The recent revocation of two pathbreaking pharmaceutical patents in India shows interesting developments in Indian patent law. Against this background, this article examines the revocation of Pfizer's Sunitinib patent and the revocation of Roche's patent for a hepatitis C drug (pegasus).

This article is part of the PLC multi-jurisdictional guide to life sciences. For a full list of jurisdictional Q&As visit www.practicallaw.com/lifesciences-mjg.